• Column Group IV GP reported a purchase of 89,200 Eikon Therapeutics common shares at USD 11.56.
• Indirect holdings reported at 4,312,139 shares via Column Group IV, 1,319,164 via Column Group Opportunity III, 148,840 via Column Group IV-A.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eikon Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-385268), on September 08, 2026, and is solely responsible for the information contained therein.